Susan G. Kreissman, MD

Professor of Pediatrics

Department:
Pediatrics

Division:
Hematology-Oncology

Mailing Address:
DUMC 102382 Durham, NC 27710

Appointment Telephone:
919-684-3401

Office Telephone:
919-684-3401

Fax:
919-681-7950

Training:
MD, Mount Sinai School of Medicine of New York University, 1985

Fellowship:
Pediatric Hematology/Oncology, Children's Hospital, Dana Farber Cancer Center (Massachusetts)

Residency:
Pediatrics, Children's Hospital at Harvard (Massachusetts), 1985-1988

Clinical Interests:
Pediatric oncology, new therapeutics for neuroblastoma, apheresis, high-dose chemotherapy, clinical trials in childhood cancer

Research Interests:
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma.  Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis.  Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). The most recent protocol is " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" completed accrual and results are being analyzed. Dr. Kreissman also serves as a member of the Neuroblastoma Strategy Group of COG, the COG Voting Body Steering Committee, and is PI for COG studies at Duke. She is involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.

Publications:
Pradhan KR, Johnson CS, Vik TA, Sender LS, Kreissman SG. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support. Pediatr Blood Cancer. 2006 Jun;46(7):793-802.

Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol. 2005 Jan;128(1):49-58.

Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS. A Randomized Comparison Between Rasburicase and Allopurinol in Children with Lymphoma or Leukemia at High Risk for Tumor Lysis BLOOD 2001 15;97:2998-3003

Croop JM, Cooper R, Fernandez C, Graves V, Kreissman S, Hanenberg H, Smith FO, Williams, DA Mobilization and collection of peripheral blood CD 34+ cells from patients with Fanconi's anemia BLOOD 2001; 98(10):2917-2921.

Kreissman S, Haase G. "Adjuvant Therapy for Childhood Cancer" in Pediatric Surgery Ed: Ashcraft (3rd edition)W.B. Saunders Philadelphia. 2000; 63: 830-858. (Book chapter)

Croop JM, Cooper R, Seshadri R, Fernandez C, Graves V, Kreissman S, Smith FO, Cornetta K, Williams DA, Abonour R. Large-scale Mobilization and Isolation of CD34+ Cells from Normal Donors. Bone Marrow Transplantation 2000; 26:1271-1279.

Asselin BL, Kreissman SG, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ. Prognostic Significance of Early Response to a Single Dose of Asparaginase in Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 1999; 21 (1):6-12.

McCarthy L, Smith FO, Emanuel D, Orazi A, Danielson C, Thompson C, Thomas C, Kreissman S. Platelet Depletion During Pediatric Peripheral Blood Progenitor Cell (PBPC) Harvesting. Transfusion Science 1998; 19:61.

Kreissman SG, Rackoff W, Lee M, Breitfeld PP. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):309-12.